Mediolanum International Funds Ltd Has $20.28 Million Stock Position in Cencora, Inc. $COR

Mediolanum International Funds Ltd lifted its position in Cencora, Inc. (NYSE:COR) by 3.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 65,443 shares of the company’s stock after buying an additional 1,958 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Cencora were worth $20,283,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in COR. T. Rowe Price Investment Management Inc. lifted its position in shares of Cencora by 160.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after acquiring an additional 4,123,795 shares in the last quarter. Norges Bank bought a new stake in shares of Cencora in the 4th quarter worth about $822,506,000. Marshall Wace LLP increased its position in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after purchasing an additional 1,672,762 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Cencora by 528.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after buying an additional 1,241,186 shares in the last quarter. Finally, Viking Global Investors LP increased its stake in shares of Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 0.1%

COR opened at $307.72 on Monday. The firm’s fifty day moving average is $279.98 and its two-hundred day moving average is $317.52. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The firm has a market cap of $59.87 billion, a PE ratio of 23.60, a price-to-earnings-growth ratio of 1.71 and a beta of 0.58. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the firm earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its Board of Directors has initiated a stock buyback plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is presently 18.40%.

Insider Activity

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of the stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the acquisition, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.38% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on COR shares. Robert W. Baird lowered their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. UBS Group increased their price target on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Citigroup decreased their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. William Blair started coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. Finally, Weiss Ratings cut Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $367.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.